NCCN 2017 Congress Series™: Biomarkers 101 - Live Webinars

The science and practice of oncology are rapidly evolving based on more complete knowledge of cancer genomes and the specific genetic events that drive cancer. This knowledge, coupled with advances in medicinal chemistry, has ushered in an era of precision oncology. Use of molecular testing followed by therapies tailored to the particular molecular landscape of a patient’s disease can allow appropriate therapies to be given to patients who are most likely to benefit, while avoiding unnecessary treatment of patients who are unlikely to benefit.  Although the availability of new cancer biomarkers is encouraging for diagnosis, prognosis and treatment decision-making, determining the clinical usefulness and selection of the appropriate testing methodologies can represent a daunting challenge for practitioners.  With the field of biomarkers rapidly advancing, clinical research directly affects how oncologists manage patients. Keeping up with advances in biomarker testing allows clinicians to offer state-of-the-art care to their patients with cancer and to better identify patients that are appropriate for biomarker-directed clinical trials.

Target Audience

This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

What Are Biomarker Tests and How Are They Approved? (11/3/2017)

  • Distinguish between diagnostic, prognostic, and predictive biomarkers in oncology.
  • Describe several different biomarker testing methodologies.
  • Explain the significance of FDA approval, Clinical Laboratory Improvement Amendments (CLIA) approval, and Molecular Diagnostic Services Program (MolDX) coverage recommendations as they apply to biomarker tests in oncology.

How Is Biomarker Testing Enriching Patient Populations for Clinical Trials & Impacting Drug Development? (11/9/2017)

  • Discuss challenges with the identification of subsets of patients with mutations appropriate for study.
  • Explain how biomarker testing/molecular profiling can improve screening for clinical trials and enhance accrual.
  • Review results of biomarker-driven clinical trials.
  • Identify circumstances under which Next Generation Sequencing (NGS) methods are appropriate for biomarker testing.

Which Biomarker Test Should I Use? (12/5/2017)

  • List important considerations for choosing appropriate testing technology.
  • Identify appropriate indications for use of a single biomarker test versus multiplex or multigene assay.
  • Recognize the importance of pathologic expertise, internal quality control standards, external quality assurance monitoring, and clinical review in determining the reliability of tumor marker testing.

Clinical Utility of Biomarkers (12/13/2017)

  • Define, in general, the concept of clinical usefulness as applied to cancer biomarker tests.
  • Review the factors considered in the evaluation of the clinical usefulness of a tumor marker in oncology.
  • Identify disease areas where data supports the use of biomarker tests in oncology.
Additional information
Supporters: 

This activity is supported by educational funding provided by Amgen.

This activity is supported by independent educational grants from AbbVie and Merck & Co., Inc.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb.

This activity is supported by educational grants from:

  • AstraZeneca
  • Daiichi Sankyo, Inc.
  • Foundation Medicine
  • Genomic Health, Inc.
  • Lilly
  • Novartis
Course summary
Course opens: 
10/12/2017
Course expires: 
12/31/2017
Cost:
$0.00

What Are Biomarker Tests and How Are They Approved?
Friday, November 3, 2017 • 12:30 - 1:30 PM EDT
Long Phi Le, MD, PhD, Massachusetts General Hospital

How Is Biomarker Testing Enriching Patient Populations for Clinical Trials & Impacting Drug Development?
Thursday, November 9, 2017 • 1:30 - 2:30 PM EST
Ross Camidge, MD, PhD, University of Colorado Cancer Center

Which Biomarker Test Should I Use?
Tuesday, December 5, 2017 • 12:00 - 1:00 PM EST
John D. Pfeifer, MD, PhD, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Clinical Utility of Biomarkers
Wednesday, December 13, 2017 • 3:00 - 4:00 PM EST
Dara L. Aisner, MD, PhD, University of Colorado Cancer Center

ALL WEBINAR TIMES ARE POSTED AS EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).

Access to participate in selected sessions is through the NCCN WebEx Site on the day of each scheduled program.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 4.0 hours of Category I credits for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 4.0 contact hours.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 4.0 contact hours (0.40 CEUs) of continuing education credit.

What Are Biomarker Tests and How Are They Approved?
Friday, November 3, 2017 • 12:30 - 1:30 PM EDT
1.0 contact hour (0.1 CEUs)
UAN: 0836-0000-17-117-L01-P

How Is Biomarker Testing Enriching Patient Populations for Clinical Trials & Impacting Drug Development?
Thursday, November 9, 2017 • 1:30 - 2:30 PM EST
1.0 contact hour (0.1 CEUs)
UAN:0836-0000-17-118-L01-P

Which Biomarker Test Should I Use?
Tuesday, December 5, 2017 • 12:00 - 1:00 PM EST
1.0 contact hour (0.1 CEUs)
UAN: 0836-0000-17-119-L01-P

Clinical Utility of Biomarkers
Wednesday, December 13, 2017 • 3:00 - 4:00 EST
1.0 contact hour (0.1 CEUs)
UAN: 0836-0000-17-120-L01-P

Available Credit

Accreditation Period

Course opens: 
10/12/2017
Course expires: 
12/31/2017
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.

Please refer to the Schedule tab for dates and times.  Check the webinars you would like to attend and click Enroll.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing